Emergent BioSolutions Inc (EBS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body's immune system. The company's biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent's commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate.

Data as of 2020-10-17
Market Cap5.796 Billion Shares Outstanding52.925 Million Avg 30-day Volume553.508 Thousand
P/E Ratio31.0 Dividend Yield EPS3.21
Price/Sales6.117 Price cash flow ratio17.4 Price free cash flow ratio24.8
Book Value22.65 Price to Tangible Book25.05 Alpha0.02
Short Interest Ratio3.76 % Short Interest to Float4.1 R-squared0.228421
BETA1.40582 52-week High/Low137.61 / 46.37 Stddev0.126324
View SEC Filings from EBS instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 6 5 20.0% 3 (0.2%) 2 (0.13%) 50.0%
Funds Holding: 293 261 12.26% 77 (5.02%) 72 (4.6%) 6.94%
13F shares: 44.379 Million 44.841 Million -1.03% 10.372 Million 9.508 Million 9.09%
% Ownership 83.8524 85.7928 -2.26% 19.5979 18.1918 7.73%
New Positions: 61 49 24.49% 15 19 -21.05%
Increased Positions 96 85 12.94% 30 19 57.89%
Closed Positions 26 22 18.18% 10 8 25.0%
Reduced Positions 110 97 13.4% 31 29 6.9%
Total Calls 93.821 Thousand 25.601 Thousand 266.47% 37 Thousand 12.5 Thousand 196.0%
Total Puts 58.133 Thousand 37.137 Thousand 56.54% 16.9 Thousand 11 Thousand 53.64%
PUT/CALL Ratio 0.62 1.45 -57.24% 0.46 0.88 -47.73%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EBS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EBS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

134 Thousand total shares from 8 transactions

Exercise Derivative Conversion (M)

7.9 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WHITE MARVIN L

  • Director
3,629 2020-10-01 2

EL-HIBRI FUAD CHAIRMAN

  • Officer
  • Director
  • 10% Owner
4,788,606 2020-09-23 16

SULLIVAN LOUIS W

  • Director
32,758 2020-09-16 4

BAILEY SUE

  • Director
32,595 2020-08-18 5

HARSANYI ZSOLT

  • Director
24,579 2020-08-17 6

JOULWAN GEORGE A

  • Director
26,771 2020-08-11 3

ZOON KATHRYN C

  • Director
12,489 2020-08-10 7

RICHARD RONALD

  • Director
8,276 2020-08-07 7

SARAN ATUL EVP, CORP DEV, GC & SECRETARY

  • Officer
39,496 2020-08-07 2

HAUER JEROME M

  • Director
10,188 2020-05-26 3

SMITH KAREN L. EVP, CHIEF MEDICAL OFFICER

  • Officer
6,310 2020-05-21 1

KRAMER ROBERT PRESIDENT AND CEO

  • Officer
  • Director
142,203 2020-05-08 2

STREI KATHERINE EVP, CHIEF HR OFFICER

  • Officer
28,009 2020-05-08 2

LINDAHL RICHARD S EVP, CHIEF FINANCIAL OFFICER

  • Officer
31,806 2020-05-08 2

HAVEY ADAM EVP, BUSINESS OPERATIONS

  • Officer
34,256 2020-04-17 3

KIRK SEAN EVP, MANUFACTURING & TECH OPS

  • Officer
12,571 2020-04-06 3

EMERGENT BIOSOLUTIONS INC.

  • SEAN KIRK, EVP, MANUFACTURING
13,604 2019-05-23 0

MULLIGAN SEAMUS

  • Director
594,162 2019-03-19 0

ABDUN-NABI DANIEL CEO

  • Officer
  • Director
144,553 2019-03-04 0

NIEDERHUBER JOHN

  • Director
No longer subject to file 2016-05-18 0

LABINGER BARRY EVP, BIOSCIENCES DIV.

  • Officer
25,182 2015-11-13 0

CHATFIELD STEVEN EVP, BIOSCIENCES

  • Officer
28,000 2013-03-14 0

INTERVAC, L.L.C.

  • 10% Owner
4,344,250 2012-09-18 0

ELSEY R DON CHIEF FINANCIAL OFFICER

  • Officer
26,614 2012-03-13 0

KEESE KYLE EVP, BIOSCIENCES DIVISION

  • Officer
18,759 2011-03-15 0

LOCKHART STEPHEN SVP PRODUCT DEVELOPMENT

  • Officer
6,980 2010-11-11 0

BIOPHARM, L.L.C.

  • 10% Owner
No longer subject to file 2010-05-27 0

ESPOSITO DENISE CLO

  • Officer
0 2009-03-10 0

BIOLOGIKA, L.L.C.

  • MEMBER 13(D) GROUP OWNING >10%
1,399,764 2008-06-04 0

ALLBAUGH JOE M

  • Director
0 2008-05-21 0

MICHIGAN BIOLOGIC PRODUCTS, INC.

  • MEMBER 13(D) GROUP OWNING >10%
1,328,018 2008-01-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WHITE MARVIN L - Director

2020-10-05 17:28:28 -0400 2020-10-01 A 3,629 a 3,629 direct -2.3268 -13.5208 0.1437 5 -13.5208 6

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-09-25 19:00:55 -0400 2020-09-24 S 12,535 $98.85 d 1,123,988 direct yes 0.6754 2.2192 2.2192 6 -3.242 5

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-09-25 19:00:55 -0400 2020-09-23 S 13,000 $100.58 d 1,136,523 direct yes 0.6754 2.2192 2.2192 6 -3.242 5

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-09-18 18:25:02 -0400 2020-09-17 S 20,000 $100.68 d 1,149,523 direct yes 0.75 3.64 3.64 6 -0.89 4

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-09-18 18:25:02 -0400 2020-09-16 S 20,000 $102.48 d 1,169,523 direct yes 0.75 3.64 3.64 6 -0.89 4

SULLIVAN LOUIS W - Director

2020-09-18 16:24:40 -0400 2020-09-16 G 10,004 d 32,758 direct 0.75 3.64 3.64 6 -0.89 4

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-09-11 21:21:56 -0400 2020-09-10 S 20,000 $102.66 d 1,189,523 direct yes -1.3536 -4.0031 0.0 1 -4.0031 6

EL-HIBRI FUAD - Director - Officer - > 10% Owner CHAIRMAN

2020-09-11 21:21:56 -0400 2020-09-09 S 20,000 $102.80 d 1,209,523 direct yes -1.3536 -4.0031 0.0 1 -4.0031 6

SULLIVAN LOUIS W - Director

2020-09-04 20:08:20 -0400 2020-09-02 S 20,525 $111.22 d 42,762 direct -0.2015 -1.3914 0.0 1 -5.8824 4

SULLIVAN LOUIS W - Director

2020-09-04 20:08:20 -0400 2020-09-02 S 7,893 $111.23 d 42,762 direct -0.2015 -1.3914 0.0 1 -5.8824 4

SULLIVAN LOUIS W - Director

2020-09-04 20:08:20 -0400 2020-09-02 M 7,893 $20.08 a 50,655 direct -0.2015 -1.3914 0.0 1 -5.8824 4

SULLIVAN LOUIS W - Director

2020-09-04 20:08:20 -0400 2020-09-02 M 7,893 a 15,786 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments